Tyrosine-kinase inhibitor

Tyrosine kinase inhibitors are novel drugs - drugs that were previously used primarily in tumors used. In a narrow sense such as chemical substances are understood, known as designer drugs are often, have been designed and optimized specifically for the inhibition of certain tyrosine kinases. There are also monoclonal antibodies to receptor tyrosine kinases. However, these are generally not referred to as " tyrosine kinase inhibitors ".

Since about the 1990s, it is known that dysregulated tyrosine kinases often play a key role in the development of tumors. Thus, the concept was developed specifically inhibit these kinases with inhibitors to treat the tumor with it. That this is indeed possible, was convincing in chronic myeloid leukemia ( CML). In CML is permanently activated and dysregulated ABL tyrosine kinase cause of the disease. Through the use of the tyrosine kinase inhibitor imatinib newly developed very good treatment success was achieved. Today, imatinib is a standard for the treatment of CML.

This success has given the research on specific tyrosine kinase inhibitors big boost and now there is a large number of such substances in preclinical testing or already in clinical use. Tyrosine kinase inhibitors are considered drugs of the future, because they act much more specific and usually do not have such a strong range of side effects as conventional cytotoxic agents.

Commercially available tyrosine kinase inhibitors

Other partially approved tyrosine kinase inhibitors are for example afatinib, Bafetinib, Dabrafenib, masitinib and Nintedanib.

Commercially available veterinary tyrosine kinase inhibitors

787962
de